![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Dynavax Expects to Resume Heplisav Testing
Dynavax Expects to Resume Heplisav Testing
June 6, 2008
Dynavax Technologies Corp. said it believes it will be able to resume clinical testing of its hepatitis B vaccine in 2009. Tests of the drug, Heplisav, were stopped by the Food and Drug Administration in April because of "a serious adverse event" in a person who received the vaccine during safety and efficacy testing.
East Bay Business Times
East Bay Business Times
Upcoming Events
-
21Oct